University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Location status: Recruiting
NCT Number: NCT06408181
The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are:
Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.
Interested in participating?
Request Info18 year–45 year
Female
Interventional
Phase 3
Philadelphia, Pennsylvania, 19104, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Aspirin is a nonsteroidal anti-inflammatory drug.
Other names: acetylsalicylic acid, ASA
Aspirin is a nonsteroidal anti-inflammatory drug.
Other names: acetylsalicylic acid, ASA
Time frame: from 20 weeks pregnancy to delivery, approximately 20 weeks
defined as two blood pressures (BPs) ≥ 140/90 mmHg at least 4 hours apart with proteinuria
Time frame: from enrollment to time of pregnancy loss, up to 24 weeks gestation
Pregnancy loss prior to 24 weeks gestation
Time frame: From enrollment to end of pregnancy, up to 38 weeks
This composite outcome will include the diagnosis of any of the following: preterm preeclampsia, term preeclampsia, gestational hypertension, preeclampsia with severe features, preeclampsia without severe features, biochemical pregnancy loss, clinical pregnancy loss
Time frame: From enrollment up to 37 weeks of pregnancy, up to 37 weeks of pregnancy
Diagnosis of preterm preeclampsia, occurring prior to 37 weeks in pregnancy
Time frame: From 37 weeks until delivery, up to 3 weeks
Diagnosis of term preeclampsia, occurring at 37 weeks or later in pregnancy
Time frame: From 20 weeks of pregnancy to delivery, approximately 20 weeks
Defined as two BPs ≥ 140/90 mmHg at least 4 hours apart without proteinuria
Time frame: From 20 weeks of pregnancy to delivery, up to 20 weeks
Diagnosis of preeclampsia with severe hypertension and/or specific signs or symptoms of significant end-organ dysfunction
Time frame: From 20 weeks of pregnancy to delivery, up to 20 weeks
defined as two BPs ≥160/110 mmHg at least 4 hours apart or any of the following lab abnormalities or symptoms: platelets <100,000/microliter, liver enzymes at least twice the normal concentration, and/or severe right upper quadrant/epigastric pain, serum creatinine > 1.1 mg/dL or a doubling of baseline serum creatinine, pulmonary edema, or new-onset cerebral or visual disturbances (headache, blurry vision). Preeclampsia super-imposed on chronic hypertension will also be considered as part of this outcome.
Time frame: From enrollment to time of pregnancy loss, up to approximately 20 weeks
Defined as losses that occur prior to identification of a gestational sac via ultrasound
Time frame: From time of first ultrasound to 20 weeks pregnancy
Defined as any pregnancy loss occurring following ultrasound confirmation of pregnancy
Time frame: From enrollment to 36 weeks 6 days of pregnancy, up to delivery
Defined as delivery at less than 37 weeks gestation
Time frame: At time of delivery
Defined as a birth weight less than 10th percentile for gestational age
Contact information is provided by the study sponsor or research team.
Enrique Schisterman, PhD
CONTACT
Kurt T Barnhart, MD
CONTACT
University of Pennsylvania
Other
Acronym: APPLE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07470320
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Oxford, United Kingdom
View Trial DetailsNCT06108947
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Trondheim, Norway
View Trial DetailsNCT04356326
Abruptio Placentae, Aspirin
Bordeaux, France
View Trial DetailsNCT03626233
Female Urogenital Diseases and Pregnancy Complications, Hypertension, Pregnancy-Induced
Créteil, France
View Trial Details